Eli Lilly and Co.'s Cyramza, or ramucirumab, gained FDA approval as a monotherapy for hepatocellular carcinoma in patients with alpha-fetoprotein levels of 400 nanograms per milliliter or higher who were previously treated with sorafenib. Cyramza is the first biomarker-driven therapy approved by the FDA as an HCC treatment.
Lilly's biomarker-driven therapy for HCC approved by FDA
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.